Novadaq Technologies Inc.TSX: NDQ

Novadaq Technologies notice of annual meeting

· Issued by Novadaq Technologies Inc. via CNW
TORONTO, June 1 /CNW/ - Novadaq(R) Technologies Inc. (TSX: NDQ), a
developer of medical imaging systems for the operating room, will be holding
its annual meeting, hosted by Dr. Arun Menawat, President and Chief Executive
Officer and Mr. Roger Deck, Chief Financial Officer.

DATE:           June 7, 2006

TIME:           10:30 am, Eastern Standard Time

LOCATION:       The Ontario Club, Canadian Room
                5th Floor, Commerce Court South
                30 Wellington Street West
                (Northeast Corner of Bay & Wellington)
                Toronto, Ontario, Canada

WEBCAST:        A live audio webcast of the call will be available at
                www.novadaq.com

                Webcast attendees are welcome to listen to the conference
                in real-time or on-demand at your convenience. The
                webcast will be archived for 90 days.

                Please connect to this website at least 15 minutes prior
                to the conference call to ensure adequate time for any
                software download that may be needed to hear the webcast.

About Novadaq Technologies
Novadaq Technologies Inc. (TSX: NDQ) develops and commercializes medical
devices based on its proprietary imaging platform for the diagnosis and
treatment of human vascular, ophthalmic, and neurologic diseases and
conditions. Novadaq's SPY(R) Intra-operative Imaging System, commercially
available worldwide, enables cardiac surgeons to visually assess coronary
vasculature and bypass graft functionality during the course of open-heart
bypass surgery. Novadaq's ophthalmic product, the OPTTX(R) System, is aimed at
the diagnosis, evaluation and treatment of wet Age-related Macular
Degeneration (AMD) by using the same core imaging technology that is used in
the SPY System. The OPTTX System is currently being evaluated in clinical
trials. Novadaq's product for nerve visualization in prostate surgery,
LUNA(TM) is being developed to enable surgeons to visualize nerve bundles
during the course of radical prostatectomy in order to reduce negative
outcomes including impotency. For more information, please visit the company's
website at www.novadaq.com.

Certain statements included in this press release may be considered
forward-looking. Such statements involve known and unknown risks,
uncertainties and other factors that may cause actual results, performance or
achievements to be materially different from those implied by such statements,
and therefore these statements should not be read as guarantees of future
performance or results. All forward-looking statements are based on Novadaq's
current beliefs as well as assumptions made by and information currently
available to Novadaq and relate to, among other things, anticipated financial
performance, business prospects, strategies, regulatory developments, market
acceptance and future commitments. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the date
of this press release. Due to risks and uncertainties, including the risks and
uncertainties identified by Novadaq in its public securities filings; actual
events may differ materially from current expectations. Novadaq disclaims any
intention or obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise.

%SEDAR: 00022069E

Novadaq Technologies Inc. on 6ix

Earlier from Novadaq Technologies

Later from Novadaq Technologies

All Novadaq Technologies news releases